Abstract
Many drugs exhibit altered pharmacokinetic parameters in burn patients. We prospectively evaluated the pharmacokinetics of ciprofloxacin in eight burn patients with active infections. Each patient received a 400-mg dose of ciprofloxacin intravenously (i.v.) every 8 h, with each dose infused over 1 h by using a rate control device. Blood samples for analysis of plasma ciprofloxacin concentrations, determined by high-performance liquid chromatography, were obtained immediately predose, at the end of the infusion, and 1, 2, 3, 4, 5, 6, and 7 h after the end of the infusion. Urine was collected from 0 to 2, 2 to 4, and 4 to 8 h following the same dose, and an aliquot was saved for determination of the ciprofloxacin concentration. Urine was also collected for 24 h prior to this dose for measurement of creatinine clearance (CLCR). Pharmacokinetic parameters were estimated by noncompartmental analysis. Mean maximum and minimum plasma ciprofloxacin concentrations were 4.2 +/- 1.1 and 0.70 +/- 0.55 microgram/ml, respectively. Mean values for clearance (CL), renal clearance (CLR), volume of distribution, terminal elimination rate constant, half-life (t1/2), and area under the concentration-time curve (AUC) were 29.1 +/- 17.5 liters/h, 13.5 +/- 10.1 liters/h, 1.75 +/- 0.41 liters/kg, 0.222 +/- 0.098 h-1, 4.5 +/- 3.9 h, and 20.7 +/- 16.6 micrograms.h/ml, respectively. CL was higher and t1/2 was shorter than noted in previous studies of acutely ill, hospitalized patients. A good correlation was noted between creatinine clearance CL(CR) and both total ciprofloxacin CL (r = 0.85) and CLR (r = 0.84). A moderate inverse correlation was noted between percent body surface area burned and total ciprofloxacin CL (r = -0.55). An AUC/MIC ratio above 125 SIT-1 (where SIT is serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in five of eight patients (63%) with a MIC of 0.25 microgram/ml. At a ciprofloxacin dosage of 400 mg i.v. every 12 h, an AUC/MIC ratio above 125 SIT-1 would have been achieved in only two of eight patients (25%). We conclude that ciprofloxacin CL is highly variable, but generally increased, in burn patients compared with that in acutely ill, general medical and surgical patients. Because of an increase in CL, a ciprofloxacin dosage of 400 mg i.v. every 8 h is more likely to produce the desired response in burn patients than the same dose given every 12 h.
Full Text
The Full Text of this article is available as a PDF (188.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bonate P. L. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet. 1990 Feb;18(2):118–130. doi: 10.2165/00003088-199018020-00003. [DOI] [PubMed] [Google Scholar]
- Boucher B. A., Kuhl D. A., Hickerson W. L. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis. 1992 Feb;14(2):458–463. doi: 10.1093/clinids/14.2.458. [DOI] [PubMed] [Google Scholar]
- Dan M., Poch F., Quassem C., Kitzes R. Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously. Antimicrob Agents Chemother. 1994 Apr;38(4):837–841. doi: 10.1128/aac.38.4.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Demling R. H. Burns. N Engl J Med. 1985 Nov 28;313(22):1389–1398. doi: 10.1056/NEJM198511283132205. [DOI] [PubMed] [Google Scholar]
- Forrest A., Ballow C. H., Nix D. E., Birmingham M. C., Schentag J. J. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993 May;37(5):1065–1072. doi: 10.1128/aac.37.5.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Forrest A., Nix D. E., Ballow C. H., Goss T. F., Birmingham M. C., Schentag J. J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073–1081. doi: 10.1128/aac.37.5.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hyatt J. M., McKinnon P. S., Zimmer G. S., Schentag J. J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995 Feb;28(2):143–160. doi: 10.2165/00003088-199528020-00005. [DOI] [PubMed] [Google Scholar]
- Krol G. J., Beck G. W., Benham T. HPLC analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids. J Pharm Biomed Anal. 1995 Dec;14(1-2):181–190. doi: 10.1016/0731-7085(95)01611-2. [DOI] [PubMed] [Google Scholar]
- Luterman A., Dacso C. C., Curreri P. W. Infections in burn patients. Am J Med. 1986 Jul 28;81(1A):45–52. doi: 10.1016/0002-9343(86)90513-9. [DOI] [PubMed] [Google Scholar]
- Yuen G. J., Drusano G. L., Forrest A., Plaisance K., Caplan E. S. Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther. 1989 Oct;46(4):451–457. doi: 10.1038/clpt.1989.164. [DOI] [PubMed] [Google Scholar]